George S Vratsanos from Englewood Cliffs, NJ, age 60

Method Of Preventing The Development Of Rheumatoid Arthritis In Subjects With Undifferentiated Arthritis
view source
US Patent:

7915222, Mar 29, 2011
Filed:

May 1, 2009
Appl. No.:

12/387359
Inventors:

George Vratsanos - Yardley PA, US
Jean-Claude Becker - Princeton NJ, US
Michael Corbo - Flemington NJ, US
Assignee:

Bristol-Myers Squibb Company - Princeton NJ
International Classification:

A61K 38/16
US Classification:

514 12
Abstract:

The invention relates to methods and compositions for treating undifferentiated arthritis (UA) and/or preventing the development of rheumatoid arthritis (RA) in subjects with UA by administering to a subject in need thereof an effective amount of soluble CTLA4 molecule.

Method For Retarding Progression To Definite Rheumatoid Arthritis In Subjects With Undifferentiated Arthritis
view source
US Patent:

8435952, May 7, 2013
Filed:

Feb 10, 2011
Appl. No.:

13/024601
Inventors:

George Vratsanos - Yardley PA, US
Jean-Claude Becker - Princeton NJ, US
Michael Corbo - Flemington NJ, US
International Classification:

A61K 38/17
A61K 39/395
US Classification:

514 212, 4241341
Abstract:

The invention relates to methods and compositions for treating undifferentiated arthritis (UA) and/or preventing the development of rheumatoid arthritis (RA) in subjects with UA by administering to a subject in need thereof an effective amount of soluble CTLA4 molecule.

Method Of Vaccinating Subjects Receiving Immune Modulating Therapy
view source
US Patent:

20080019999, Jan 24, 2008
Filed:

May 8, 2007
Appl. No.:

11/800860
Inventors:

George Vratsanos - Yardley PA, US
Francisco Leon - Bethesda MD, US
Lee Tay - Princeton Junction NJ, US
Kenneth Bahrt - Edison NJ, US
International Classification:

A61K 39/145
A61K 39/02
A61P 31/16
US Classification:

424209100, 424236100, 424244100
Abstract:

The present invention relates to methods of vaccinating subjects receiving immune modulating therapy, such as soluble CTLA4 molecules, for treatment of immune system diseases mediated by T-cell interactions with B7-positive cells including, but not limited to, autoimmune diseases, immunoproliferative diseases, and immune disorders associated with graft transplantation.

George S Vratsanos